BridgeBio Oncology Therapeutics released a corporate deck outlining three Phase 1 RAS-pathway programs with clinical data supporting continued development.
Lead priority: BBO-8520 with pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC; ORR 75% at 500 mg QD.
Across dose levels, the combination showed 53% ORR in G12C inhibitor-experienced patients; management highlighted a differentiated liver-safety profile.
BBO-11818 pan-KRAS and BBO-10203 RAS:PI3Kα programs remain active; additional readouts flagged for Q4 2026 and mid-2027.
Cash reported at USD 344 million at end-Q2 2026; runway projected into 2028.
BBOT•
